ReviewPharmacoEconomics2017
The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment.
Review in PharmacoEconomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 5 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- Health state utility estimates for value assessments of novel treatments in Huntington's disease: a systematic literature review.Health and quality of life outcomes · 2024Pooled it
- China Health Related Outcomes Measures (CHROME): Development of a New Generic Preference-Based Measure for the Chinese Population.PharmacoEconomics · 2022Pooled it
- 'Mapping' Health State Utility Values from Non-preference-Based Measures: A Systematic Literature Review in Rare Diseases.PharmacoEconomics · 2020Pooled it
- Valuing health-related quality of life in heart failure: a systematic review of methods to derive quality-adjusted life years (QALYs) in trial-based cost-utility analyses.Heart failure reviews · 2019Pooled it
- A systematic review of utility values in children with cerebral palsy.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2019Pooled it
- Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment.PharmacoEconomics · 2021Trial
- Quality of life utility-Core 10 dimensions (QLU-C10D) scores based on cancer patients' health preferences are more sensitive than those based on general public's health preferences.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Cancer specific health utilities - QLU-C10D country value sets for Belgium, Hungary, Portugal and the Republic of Korea - an international valuation study.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Measuring health-related quality of life in multiple sclerosis: comparing the acceptability, validity and responsiveness of the EQ-5D-3L and MSIS-8D.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- United Kingdom value set for the functional assessment of cancer therapy eight dimension (FACT-8D) preference-based quality of life instrument.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Japanese value set for the Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D) cancer-specific preference-based quality of life instrument.Health and quality of life outcomes · 2025Article
- Validation and comparison of EQ-5D-5L and SF-6Dv1 in myopic patients requiring corneal refractive surgery in China.Health and quality of life outcomes · 2025Article
- Validation of the Cancer-Specific Preference-Based Measure EORTC QLU-C10D against the Generic Instruments EQ-5D-5L and SF-6Dv2 in a Prospectively Collected Sample of Patients with Cancer in Austria and France.PharmacoEconomics · 2025Article
- Validation of the cancer-specific utility measure EORTC QLU-C10D using evidence from four lung cancer trials covering six country value sets.Scientific reports · 2025Article
- A framework for extending the health-related quality adjusted life year by combining instruments.Health and quality of life outcomes · 2025Article
- The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Assessing the reliability of a novel cancer-specific multi-attribute utility instrument (FACT-8D) and comparing its validity to EQ-5D-5L in colorectal cancer patients.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
- Development of a value-based scoring system for the MobQoL-7D: a novel tool for measuring quality-adjusted life years in the context of mobility impairment.Disability and rehabilitation · 2024Article
- A comparison of measurement properties between EORTC QLU-C10D and FACT-8D in patients with hematological malignances.Health economics review · 2024Article
- Psychometric Properties of the EQ-5D-5L in Patients with Alopecia Areata.PharmacoEconomics - open · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A condition-specific preference-based measure (CSPBM) is a measure of health-related quality of life (HRQOL) that is specific to a certain condition or disease and that can be used to obtain the quality adjustment weight of the quality-adjusted life-year (QALY) for use in economic models. This article provides an overview of the role and the development of CSPBMs, and presents a description of existing CSPBMs in the literature. The article also provides an overview of the psychometric properties of CSPBMs in comparison with generic preference-based measures (generic PBMs), and considers the advantages and disadvantages of CSPBMs in comparison with generic PBMs. CSPBMs typically include dimensions that are important for that condition but may not be important across all patient groups. There are a large number of CSPBMs across a wide range of conditions, and these vary from covering a wide range of dimensions to more symptomatic or uni-dimensional measures. Psychometric evidence is limited but suggests that CSPBMs offer an advantage in more accurate measurement of milder health states. The mean change and standard deviation can differ for CSPBMs and generic PBMs, and this may impact on incremental cost-effectiveness ratios. CSPBMs have a useful role in HTA where a generic PBM is not appropriate, sensitive or responsive. However, due to issues of comparability across different patient groups and interventions, their usage in health technology assessment is often limited to conditions where it is inappropriate to use a generic PBM or sensitivity analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.